IDEAS home Printed from
   My bibliography  Save this article

Why Lower Drug Prices Benefit Institutional Investors: an application of universal ownership theory


  • Steve Lippman
  • Daniel E. Rosan

    (Interfaith Center on Corporate Responsibility)

  • Adam Seitchik

    (Trillium Asset Management)


Changes in prescription drug prices have broad ripple effects across the diverse portfolios that most institutional investors hold. Lower prices cut into pharmaceutical company profits, but improve the overall productivity and profitability of other investable sectors of the economy. This paper considers the net impact of cuts in drug prices on investor portfolios. We find that falls in pharmaceutical company profits resulting from price cuts would be largely if not fully offset by a combination of health plan cost-savings and increases in consumer spending power. Furthermore, falling drug prices benefit investors through the dynamic benefits from a healthier workforce with greater access to prescription drugs. We conclude that, from the perspective of the broadly diversified "universal investor", support for lower drug prices is consistent with a fiduciary duty to seek attractive long-term returns at the portfolio level. Strategies for shareholder activism should be expanded, including engagement with corporate health care purchasers and advocacy for public policy reform. Copyright (c) 2007 The Authors; Journal compilation (c) 2007 Blackwell Publishing Ltd.

Suggested Citation

  • Steve Lippman & Daniel E. Rosan & Adam Seitchik, 2007. "Why Lower Drug Prices Benefit Institutional Investors: an application of universal ownership theory," Corporate Governance: An International Review, Wiley Blackwell, vol. 15(3), pages 455-466, May.
  • Handle: RePEc:bla:corgov:v:15:y:2007:i:3:p:455-466

    Download full text from publisher

    File URL:
    File Function: link to full text
    Download Restriction: Access to full text is restricted to subscribers.

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    1. F. M. Scherer, 1993. "Pricing, Profits, and Technological Progress in the Pharmaceutical Industry," Journal of Economic Perspectives, American Economic Association, vol. 7(3), pages 97-115, Summer.
    Full references (including those not matched with items on IDEAS)

    More about this item


    Access and download statistics


    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bla:corgov:v:15:y:2007:i:3:p:455-466. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Wiley-Blackwell Digital Licensing) or (Christopher F. Baum). General contact details of provider: .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.